Available online at www.jobpcr.com

ISSN-2394:3076
CODEN(USA) : JBPCBK
Journal of Biological Pharmaceutical And Chemical Research, 2023, 10(1): 1-24

(http://www.jobpcr.com/arhcive.php)

Exploring the potential of microbiota transplantation as a novel approach for treating infectious and inflammatory diseases.

Ishan Tiwari

Amity Institute of Microbial Technology, Amity University Uttar Pradesh, Noida , India

Corresponding author: ishan.tiwari@s.amity.edu

ABSTRACT

Fecal microbiota transplantation (FMT) is a promising new approach for treating various infectious and inflammatory diseases by restoring a healthy gut microbiome. FMT involves transferring fecal material from a healthy donor into the gastrointestinal tract of a recipient. This book chapter explores the current research on FMT as a treatment for Clostridium difficile infection, inflammatory bowel disease, metabolic syndrome, autoimmune diseases, neurological disorders, and liver disorders. FMT has shown high cure rates for C. difficile infection and has been approved by regulatory agencies for this indication. However, challenges remain in developing FMT as a therapeutic approach for other diseases, including standardization of donor screening and faecal material preparation, regulatory approval, and the need for trained healthcare professionals and infrastructure for FMT administration. Despite these challenges, FMT holds promising potential as a novel and effective treatment approach for a wide range of diseases. This chapter provides an overview of the current state of FMT research and highlights the need for further investigation and development of this innovative therapeutic approach. With continued research and collaboration between researchers, clinicians, and regulators, FMT has the potential to revolutionize the treatment of infectious and inflammatory diseases.

Keywords: microbiome, transplant, gut, bacteria, donor, regulation

INTRODUCTION

The incidence of chronic immune and inflammatory disorders such as asthma, food allergies, and inflammatory bowel disease (IBD) is rapidly increasing globally. While genetic factors cannot fully account for this trend, environmental factors are believed to play a remarkable role in the pathogenesis of these conditions. The westernization of many countries, characterized by practices such as high rates of Caesarean section, overuse of antibiotics, and a shift towards protein-rich, high-calorie diets, has been linked to these trends. Changes in the gut microbiota due to these practices may explain the significant rise in the incidence of IBD, food allergies, and asthma. The gut microbiota serves as an essential organ with functional traits that are not encoded in the human genome, and most intestinal bacteria possess catabolic enzymes that produce short-chain fatty acids (SCFAs) by fermenting complex polysaccharides indigestible to humans. SCFAs provide energy to the host and have anti-

inflammatory and anti-carcinogenic properties by modulating cytokine production and promoting gastrointestinal epithelial barrier integrity. Maintaining the regulation and functions of the gut microbiota is crucial for the overall health of the host. Interventions targeting the gut microbiota offer a promising approach for treating disorders associated with bacterial imbalances.

In recent years, the incidence, morbidity, and mortality of Clostridium difficile infection (CDI) have significantly increased worldwide. Antibiotic treatments that disrupt the gut microbiota are the primary culprits responsible for this trend. C. difficile spores can germinate and cause inflammation and debilitating diarrhoea in vulnerable individuals, producing enterotoxins that contribute to the pathogenesis of CDI. Despite antibiotics being the standard treatment for CDI, they can also lead to recurrent CDI by further suppressing the native gut microbiota. Faecal microbiota transplantation (FMT) has emerged as a highly effective rescue treatment for recurrent CDI, as it restores the composition and functionality of the gut microbiota. In addition, FMT is also being investigated as a potential treatment for acute and severe forms of CDI that do not respond to antibiotic treatment. While FMT is a promising therapeutic approach, developing next-generation FMT-based therapeutics that can be standardized for efficacy and approved by regulatory agencies requires a mechanistic understanding of how FMT works. Such understanding can also help in the development of standard therapeutics, such as specific molecules or defined microbial drugs, aimed at modulating the gut microbiota.

Recent advances in high-throughput microbial genomic sequencing and other systems biology techniques have provided a greater understanding of the potential role of gut microbiota in the development of various diseases. Changes in the composition and function of gut microbiota have been observed in many diseases; however, it remains uncertain whether these changes are a cause, a consequence, or simply an incidental finding. One approach to addressing this uncertainty is to restore the gut microbiota to its pre-disease state, which has gained interest as a novel therapeutic strategy. Fecal microbiota transplantation (FMT) is one such approach where screened stool from healthy donors is transferred to the gastrointestinal tract of patients. While FMT is currently only recommended for recurrent Clostridioides difficile infection, ongoing clinical trials worldwide are exploring its potential for other therapeutic indications. The use of microbial genomic sequencing has led to a growing understanding of the role of microbiota in maintaining health and contributing to various diseases (Kang et al., 2017; Lynch & Pedersen, 2016).

The human gastrointestinal tract houses a complex microbial community that includes bacteria, archaea, viruses, and fungi. While there is no universally accepted definition of a healthy gut microbiota, studies have shown that high microbial diversity, stability, and redundancy of major functions are key markers of a healthy state (Bäumler and Sperandio, 2016). Perturbations in the gut microbiota, known as dysbiosis, have been linked to various diseases, leading to a growing interest in fecal microbiota transplantation (FMT) as a potential therapeutic strategy. FMT involves the transfer of pre-screened donor stool into the gastrointestinal tract of a patient, with the aim of correcting imbalances, increasing overall diversity, and restoring the functionality of the microbiota (Kump et al., 2020).

Clostridioides difficile (C. *difficile*) is a major public health threat that causes the most common healthcare-associated infection. The disease is associated with gut microbiota dysbiosis, which is best characterized in this condition. Antibiotic use is a major risk factor for *C. difficile* infection, and antibiotic-mediated perturbation of the gut microbiota has consistently been observed in affected patients (Petrof and Khoruts, 2014). Up to 30% of patients experience recurrent *C. difficile* infection

following treatment of the initial infection, and some patients fail to respond to multiple and prolonged courses of antibiotics (Lynch and Pedersen, 2016). The concept of restoring the composition and functionality of the gut microbiota to a pre-antibiotic state has emerged as a potential therapeutic approach for the condition. FMT has been considered as a viable treatment for *C. difficile* infection since the 1950s, with a growing number of case reports and case series supporting its efficacy (van Nood et al., 2013) (Allegretti et al., 2019).

MATERIAL AND METHODS

This paper aims to explore the potential of microbiota transplantation, specifically fecal microbiota transplantation (FMT), as a novel approach for treating infectious and inflammatory diseases. In order to achieve this objective, a comprehensive search of scientific literature was conducted using electronic databases, including PubMed, Scopus, and Web of Science. The search terms used included "microbiota transplantation," "fecal microbiota transplantation," "FMT," "infectious diseases," "inflammatory diseases," and related keywords. The search was limited to articles published in English.

The identified articles were then screened based on their relevance to the topic. Studies focusing on the use of FMT for the treatment of infectious and inflammatory diseases, including but not limited to Clostridium difficile infection, inflammatory bowel disease, autoimmune diseases, neurological disorders, and liver disorders, were included for further analysis.

Data extraction was performed to gather relevant information from the selected studies. This included details on study design, patient characteristics, intervention protocols, outcomes, and follow-up duration. The extracted data were organized and synthesized to provide a comprehensive overview of the findings related to the potential of FMT in treating infectious and inflammatory diseases.

In addition to the primary studies, relevant systematic reviews, meta-analyses, and clinical practice guidelines were also reviewed to gain a broader perspective on the current evidence and recommendations regarding FMT.

Ethical considerations were taken into account by ensuring that the information presented in this review paper is based on previously published studies and does not involve any personal or identifiable patient data.

The limitations of the reviewed studies and the potential biases inherent in the available literature were critically assessed and discussed.

History of FMT

The practice of fecal microbiota transplantation (FMT) dates back to ancient China during the fourth century, where human fecal material was used to treat severe diarrhea. This practice continued until the sixteenth century Ming Dynasty when fresh or fermented fecal suspensions were used to treat patients with gastrointestinal (GI) conditions such as diarrhea, constipation, and abdominal pain. In 1958, Eiseman and colleagues reported the first medical literature of FMT being used to successfully treat patients with pseudomembranous colitis. Veterinary medicine widely used the term "transfaunation" to describe the transference of gastrointestinal content from a healthy to a sick animal. The first randomized controlled trial was conducted by Els et al. in 2013, demonstrating the effectiveness of donor faeces duodenal infusion in resolving recurrent Clostridioides difficile infection (CDI) symptoms. Later studies confirmed the high cure rates of recurrent and refractory

CDI with FMT. Borody et al. published the earliest non-infectious disease application of FMT in 1989, performing an exchange of bowel flora on a 45-year-old male with refractory ulcerative colitis, showing full and lasting clinical recovery after treatment. As the clinical use of FMT shifted from infectious to non-communicable disorders, its range of applications expanded rapidly. Moreover, new insights connecting gut microbiota to extraintestinal diseases would further expand the clinical practice of FMT (Suez et al., 2018).

The role of the microbiome in infectious and inflammatory diseases

The gut microbiota plays a significant role in shaping the development of the adaptive immune system. By the age of three, the gut microbiota has matured, and during this period, it helps transition the mucosal immune system from neonatal to adult status. The gut microbiota stimulates the development of a TH1 phenotype and IgA secretion, inhibiting IgE synthesis and reducing antigen presentation to the mucosal immune system, which leads to tolerance to food allergens. In adulthood, the gut microbiota generates signals that modulate both innate and adaptive immunity, such as microbial-associated molecular patterns that stimulate receptors on the epithelial surface. These receptors induce the secretion of anti-bacterial peptides that prevent invasion by potential pathogens (Budden et al., 2017).

Probiotics are live microorganisms that provide health benefits when consumed in adequate amounts, and they have gained popularity in recent years due to their potential to improve human health. The concept of using probiotics was first introduced by Elie Metchnikoff, who discovered Lactobacillus bulgaricus, a bacterium found in fermented yogurt consumed by Bulgarian inhabitants associated with longevity and good health. Other probiotics were then investigated, and the term "probiotic" was officially coined in 1965. According to the FAO/WHO Expert Consultation, probiotics are defined as live microorganisms that provide health benefits to the host. Probiotics can be found in functional foods like fermented dairy products and dietary supplements and have been shown to improve human health in different aspects, including digestive conditions like diarrhea, irritable bowel syndrome, and inflammatory bowel disease (Hill et al., 2014).

Dysbiosis, defined as an imbalance in the composition of the tissue-resident microbiota, is associated with various disorders, such as metabolic syndrome and allergic disorders (Molina-Tijeras et al., 2019). Numerous studies have established a connection between the composition of gut microbiota and the health of the host, suggesting that the appropriate development of the immune response is reliant on gastrointestinal colonization by an adequate microbiota. Probiotics have been extensively used to reverse dysbiosis and modulate the host immune response. Although the exact mechanisms by which probiotics improve the intestinal barrier function are not fully understood, some studies suggest that the beneficial effects of probiotics may include the enhancement of the intestinal epithelial barrier function (Molina-Tijeras et al., 2019). Research has demonstrated that certain probiotic strains directly enhance tight junction protein expression and/or localization both in vivo and in vitro. The effects of probiotics on pathogens are attributed to their ability to adhere to the intestinal mucosa and/or produce antimicrobial substances. Probiotic strains like Lactobacilli and Bifidobacteria produce surface proteins such as adhesins, that help them attach to the mucus layer, providing protection against pathogens from the intestinal lumen. They also produce bacteriocins, including lactacin B and plantaricin, that act against pathogens through the destruction of target cells or inhibition of cell wall synthesis. Probiotics also produce short-chain fatty acids (SCFAs) like acetic, propionic, and butyric acids, which support the epithelial barrier function in the intestine. Probiotics interact with different immune cells located in the intestine, including epithelial cells, dendritic cells,

monocytes/macrophages, and lymphocytes. Probiotic strains differentially regulate the expression and secretion of antimicrobial peptides and chemokines, typically suppressing proinflammatory responses and promoting a tolerogenic response. Probiotics also induce the release of antimicrobial peptides (AMPs), including α- and β-defensins and cathelicidins, by different host cells of the innate immune response, which disrupt bacterial integrity (Molina-Tijeras et al., 2019). Although probiotics have a well-established safety record, some reports have linked probiotics to infections in immunocompromised individuals and those with indwelling medical devices, emphasizing the importance of caution when using probiotics.

Fecal microbiota transplantation (FMT) has been recognized as a promising approach to restore the balance of gut microbiota in patients with various diseases (Zhao et al., 2023). This therapy involves the transfer of processed fecal materials from healthy donors to patients, which helps to rebuild the balance of gut microbiota and treat diseases. The human gastrointestinal tract is normally colonized with a diverse range of bacteria that remain relatively stable over time, but genetic and environmental factors such as diet, viruses, and drug use can disrupt this balance and cause disease. Additionally, some diseases can also lead to imbalances in the gut microbiota.



Fig.1 Diagrammatic representation of fecal transplantation

In 2013, the first randomized controlled trial was conducted to demonstrate the efficacy of FMT in resolving Clostridium difficile infection (CDI) symptoms. Since then, FMT has gained recognition in the treatment of antibiotic-refractory CDI and has been applied to various other diseases, including autoimmune diseases, behavioural diseases, metabolic disorders, and organic diseases (Zhao et al., 2023). Professional societies have also endorsed FMT for the treatment of antibiotic-refractory CDI.

There is growing evidence to suggest that the gut microbiota and the gut-liver axis are linked to a range of liver diseases, including alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), viral hepatitis, cirrhosis, primary sclerosing cholangitis (PSC), and hepatocellular carcinoma (HCC) (Schnabl and Brenner, 2014). An imbalance in the gut microbiota could contribute to the development, progression, and prognosis of these liver diseases. Fecal microbiota transplantation, a method that has been used since the 4th century, has emerged as a potential solution to restore normal gut microbiota in patients with chronic liver diseases. In recent years, FMT has gained significant attention in clinical trials as a novel method to rebalance the intestinal microecology and manage chronic liver diseases.

Mechanisms of action of fecal microbiota transplantation (FMT)

The use of antibiotics can disrupt the gut microbiome, leading to the overgrowth of enterotoxin-producing C. difficile bacteria, causing inflammation and diarrhea. Fecal microbiota transplantation (FMT) has emerged as an effective treatment for C. difficile infection (CDI) as it restores the gut microbiome to a healthy state, thereby reintroducing "healthy commensals" to compete with

pathogens, a phenomenon known as "colonization resistance." (Kassam et al., 2013) Although the gut microbiome plays an important role in the pathogenesis of various diseases, its contribution varies from one disease to another. For CDI and inflammatory bowel disease (IBD), changes in gut microbiome composition are significant factors in disease pathogenesis. (Sartor, 2008) However, for other diseases, the role of the gut microbiome may be less significant than other factors. Although FMT is widely accepted as an effective treatment for rCDI, recent research suggests that FMT's effectiveness may not be solely due to the restoration of gut bacteria. A sterile fecal filtrate rich in soluble factors associated with bacteria can effectively treat rCDI comparable to conventional FMT, indicating the presence of these factors as a potential mechanism behind FMT's efficacy. (Wang et al., 2021)

- **Bacteriophages alteration:**

Bacteriophages, viruses that replicate within bacteria or archaea, have been found to play a significant role in altering the virulence and biofilm of their hosts. In studies on fecal microbiota transplantation (FMT) for the treatment of Clostridium difficile infection (CDI), it has been observed that the abundance of Caudovirales, a type of bacteriophage, decreases significantly in stool after FMT, and the success of FMT is more likely if donors have a higher fraction of Caudovirales in their stool virome (Draper et al., 2018). The recipient's core virome after FMT for rCDI resembles that of the donor and remains stable for at least 7 to 12 months, while low eukaryotic viral richness in recipients before FMT is associated with successful FMT for inflammatory bowel disease (IBD) (Zuo et al., 2018). In a mouse study, transferring a lean fecal virome into mice fed with a high-fat diet resulted in reduced weight gain and normalized blood glucose relative to control mice, indicating that the fecal virome exerts its effects via changes in the gut microbiota (Wang et al., 2019). While the role of bacteriophages and the virome in successful FMT is not yet fully understood, studies suggest that bacteriophages can reprogram the metabolism of their bacterial hosts, including the transfer of phage genes that encode for antibiotic resistance and alterations in pathogen virulence (Duerkop et al., 2016). Further exploration is required to determine the exact mechanisms behind the success of FMT, taking into account the potential confounding factor of eukaryotic viruses found in food (Draper et al., 2018).

- **Mycobiota alterations:**

Fungi play a potential role in the efficacy of FMT for CDI. Studies suggest that successful FMT is associated with colonization by certain donor-derived fungal taxa, such as Saccharomyces and Aspergillus, while non-response is linked to the dominance of Candida in the donor stool. Conversely, individuals treated with antibiotics alone retained Candida overgrowth. In a mouse model, the presence of Candida albicans reduced FMT efficacy, which could be restored with antifungal therapy. Studies have shown that the fungal microbiota is imbalanced in IBD, with a high Basidiomycota/Ascomycota ratio and a low proportion of Saccharomyces cerevisiae but high proportion of C. albicans compared to healthy individuals. Moreover, studies on FMT for ulcerative colitis found that high Candida abundance pre-FMT was linked to clinical response, while decreased Candida abundance post-FMT was linked to reduced disease severity. However, the significance of gut fungi in FMT efficacy remains unclear, and changes in gut mycobiota profiles may only be proxies of gut bacterial alterations. The specific contribution of fungi to FMT efficacy is undefined, although trans-kingdom-fungi-bacteria interactions have been observed in various ecosystems and are being studied in the gut. The role of bacteriophages in FMT efficacy is also unclear, although studies suggest that they can reprogram the metabolism of their bacterial hosts.

- **Metabonomics:**

Metabonomic is a field that utilizes quantitative measurements of metabolic responses over time to interventions or treatments. Unlike metabolomics, which focuses on metabolic responses in cells or tissues, metabonomic examines responses in an individual or community. By analysing "real" metabolic endpoints, metabonomic applies integrated-systems biology to investigate the metabolic status of an organism or ecosystem. Recent research has shown that the role of gut microbiota-derived metabolites, particularly short-chain fatty acids (SCFAs), is a crucial area of interest in understanding the mechanisms of FMT.

- **Short-chain fatty acids:**

Short-chain fatty acids (SCFAs) are produced through bacterial fermentation of partially digestible and non-digestible dietary carbohydrates and amino acids. Numerous studies have investigated the role of SCFAs in FMT, particularly in the context of C. difficile infection (CDI). Research has shown that SCFAs play a critical role in protecting against C. difficile growth, with higher levels of SCFAs correlating with lower CDI risk. Among the SCFAs, valerate has been found to inhibit the growth of C. difficile in vitro and in mouse models of CDI. Successful FMT for recurrent CDI in humans has also been associated with the restoration of stool valerate levels. SCFAs, specifically butyrate, have also been shown to promote regulatory T-cell response in murine models of inflammatory bowel disease (IBD). The analysis of gut microbiota in FMT-treated mice has shown significant increases in commensals, including SCFA-producing families such as Ruminococcaceae and Lachnospiraceae, suggesting that restoration of gut microbial SCFA producers through FMT may drive regulatory immunological responses and homeostatic balance in IBD

- **Bile acids:**

The study of bile acids has been an important area of research in the context of FMT/CDI. In vitro experiments conducted over a decade ago showed that different classes of bile acids have varying effects on C. difficile. Primary bile acids, such as taurocholic acid (TCA), promote spore germination and have a pro-C. difficile effect, while secondary bile acids, such as deoxycholic and lithocholic acid, inhibit vegetative growth and toxin activity, thus having an anti-C. difficile effect. The gut microbiota plays a critical role in the conversion of primary to secondary bile acids, and studies have shown that FMT can restore the gut microbiota's bile-metabolizing capacity, leading to the production of high levels of secondary bile acids. Successful FMT for CDI has been associated with an increase in circulating fibroblast growth factor (FGF)-19 and a reduction in FGF-21, consistent with upregulation of the bile-acid receptor farnesoid X receptor (FXR)-FGF pathway. Bacteria with 7-α-dehydroxylase bile-metabolizing activity, such as Clostridium scindens, produce tryptophan-derived antibiotics that inhibit the cell division of C. difficile. The changes in bile-acid-FXR interactions brought about by FMT may have other beneficial effects, such as reducing colonic inflammation, promoting the generation of peripheral regulatory T cells, and regulating the size and function of the colonic regulatory T-cell population. (Buffie, Bajic, & Schloss, 2018; Wilson et al., 2021)

The gut microbiota plays a significant role in the development of adaptive immunity, with its structure and function being fully mature by the age of three in all human populations studied so far. This period coincides with the development of major components of adaptive immunity, and the gut microbiota is essential in reprogramming the mucosal immune system from neonatal to adult status. During pregnancy, the foetus has a dominant TH2 response to prevent rejection, but after birth, TH2 dominance increases the risk of allergic diseases by activating mast cells. (Belkaid & Hand, 2014;

Round & Mazmanian, 2009.)

The gut microbiota plays a vital role in modulating both innate and adaptive immunity. It generates various signals that continually stimulate receptors on the epithelial surface, such as NOD and Toll-like receptors (TLR), inducing anti-bacterial peptide secretion, and preventing potential pathogen invasion (Belkaid & Hand, 2014). In addition, the gut microbiota generates short-chain fatty acids (SCFAs) such as butyrate and acetate that are critical for maintaining intestinal barrier integrity,



Table 1: List of bacteria that have been identified in FMT

blocking bacterial antigens from directly contacting epithelial Toll-like receptors, and preventing the activation of immune responses (Round & Mazmanian, 2009). Recent studies have shown that the gut microbiota mediates T cell differentiation and cytokine secretion (Round & Mazmanian, 2009). Some species, like Lactobacillus plantarum, can attenuate the downstream transduction of TLR4 signalling pathways and induce lipopolysaccharide tolerance (Belkaid & Hand, 2014). Additionally, several bacterial species can promote regulatory T cells (Treg). For instance, Bacteroides fragilis stimulates a Foxp3+ Treg response through the activation of the TLR2 signalling pathway by polysaccharide A (PSA) (Round & Mazmanian, 2009). Similarly, members of the Clostridium genus provide a TGF-β-rich environment that promotes the accumulation of Foxp3+ Treg cells (Belkaid & Hand, 2014). Faecalibacterium prausnitzii has been shown to upregulate interleukin 10 (IL-10)-producing Treg cells in the gut (Belkaid & Hand, 2014). Furthermore, recent research has demonstrated that the effects of such modulation may not be limited to the gastrointestinal tract alone. For instance, dendritic cells exposed to gut microbiota metabolites can be recruited to other body sites during inflammation and influence immune responses at the new location (Round & Mazmanian, 2009).

Bacteria	Description
Bacteroidetes	Gram-negative, anaerobic, rod-shaped bacteria that are commonly found in the human gut. Some species have been associated with a healthy gut microbiome.
Firmicutes	Gram-positive, anaerobic, rod-shaped bacteria that are also commonly found in the human gut. Some species have been associated with obesity and other metabolic disorders.
Proteobacteria	A diverse group of Gram-negative bacteria that includes many pathogens, such as Escherichia coli and Salmonella. Some species have also been found in the gut microbiota of healthy individuals.
Actinobacteria	Gram-positive, aerobic, rod-shaped bacteria that are found in a variety of environments, including soil and water. Some species have been associated with the production of antibiotics and other bioactive compounds.
Verrucomicrobia	Gram-negative, anaerobic, rod-shaped bacteria that are relatively rare in the human gut. One species, Akkermansia muciniphila, has been associated with a healthy gut microbiome and improved metabolic health.
Fusobacteria	Gram-negative, anaerobic, spindle-shaped bacteria that are found in the human oral cavity and gut. Some species have been associated with periodontal disease and colorectal cancer.

Efficacy and safety of FMT for treating Clostridioides difficile infection (CDI)

Clostridioides difficile infection (CDI) is a severe and potentially life-threatening disease that is commonly treated with antibiotics, but recurrence rates are high, and antibiotics can further disrupt the gut microbiome, leading to complications (Leffler & Lamont, 2015). Fecal microbiota transplantation (FMT) has emerged as a promising alternative treatment for CDI since it restores gut microbiota balance and eradicates the infection (van Nood et al., 2013). Several studies have shown that FMT is highly effective in treating recurrent CDI, with cure rates of over 80% (Quraishi et al., 2017). Furthermore, FMT has been shown to be safe, with few serious adverse events reported (Cammarota et al., 2017). Nonetheless, the long-term safety and efficacy of FMT are unclear, and further research is needed to fully understand the potential risks and benefits of this therapy (Kelly et al., 2015).

Regulatory bodies such as the FDA and the European Medicines Agency have issued guidelines for the use of FMT in clinical practice to ensure its safe and appropriate use (Cammarota et al., 2017). These guidelines include donor screening and testing for infectious diseases, informed consent from patients, and appropriate dosing and administration methods. Overall, FMT is a promising therapy for CDI that has shown high efficacy and safety, but further research and regulatory oversight are needed to ensure its appropriate use and to fully understand its long-term effects.

Fecal microbiota transplantation (FMT) has emerged as a promising therapy for treating Clostridioides difficile infection (CDI), with numerous studies demonstrating its efficacy and safety. In a randomized controlled trial conducted by van Nood et al., FMT was found to be highly effective in treating CDI, with a resolution rate of 94% within 10 days, compared to only 31% for vancomycin treatment alone (van Nood et al., 2013). Similarly, Cammarota et al. found that 96% of patients receiving FMT achieved clinical resolution of CDI symptoms compared to only 31% of patients in the control group (Cammarota et al., 2017). A systematic review and meta-analysis of 27 studies also showed a pooled cure rate of 85% with FMT treatment for CDI (Quraishi et al., 2017). FMT has been reported to be generally well-tolerated, with few adverse events reported. However, regulatory agencies have issued guidelines for donor and material screening and testing to mitigate the potential risks associated with FMT (Cammarota et al., 2017). The use of frozen and thawed fecal material has also been shown to be just as effective as fresh material, with additional safety benefits through increased testing and screening prior to use (Kelly et al., 2015). Furthermore, a meta-analysis by Jiang et al. of 14 randomized controlled trials and 21 non-randomized studies showed that FMT was highly effective for recurrent CDI, with a clinical resolution rate of 87.1% and a lower risk of adverse events compared to standard antibiotic therapy (Jiang et al., 2020). The study also found that FMT had a lower rate of recurrent CDI compared to antibiotics alone, with a rate of 0.1% for FMT versus 30.6% for antibiotics alone (Jiang et al., 2020). Despite the promising results, further research is needed to fully understand the long-term safety and efficacy of FMT for CDI.

Table 2: Cure Rates of FMT For Various Conditions {Kelly et.al (2014)}

Condition	**Cure Rate**
Clostridioides difficile infection (CDI)	Up to 90%
Inflammatory bowel disease (IBD)	30-60%
Irritable bowel syndrome (IBS)	70%
Multidrug-resistant organisms (MDRO) colonization	80-100%
Graft-versus-host disease (GVHD)	50-70%
Non-alcoholic steatohepatitis (NASH)	35%
Autism spectrum disorder (ASD)	20-25%

Despite the promising results of FMT in treating recurrent CDI, concerns have been raised about the potential transmission of infectious agents from the donor to the recipient. The FDA has issued safety alerts regarding the transmission of multi-drug resistant organisms (MDROs) and other infectious agents. To address these concerns, the FDA has implemented regulations for donor screening and selection, as well as the processing and testing of fecal material before transplantation to reduce the risk of infectious agent transmission. It is important to note that although FMT has shown high efficacy and safety in treating CDI, further research is needed to determine the optimal method of

delivery, long-term safety and efficacy, and potential risks associated with the use of FMT. Standardized protocols for donor selection, screening, and processing, as well as FMT administration, will be essential to ensure the safety and efficacy of this therapy.

FMT as a potential treatment for inflammatory bowel disease (IBD)

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder that affects the digestive tract, and its etiology remains unknown. There is a complex interplay between genetic, environmental, and immunological factors that contribute to IBD's development. While the typical treatments for IBD include anti-inflammatory drugs, immunosuppressants, and biologic agents, these treatments may be costly, have side effects, and may not always be effective. FMT has been suggested as a potential treatment for IBD due to its capacity to modify the gut microbiota and reduce inflammation. Several preliminary clinical studies have shown promising results in the treatment of both ulcerative colitis (UC) and Crohn's disease (CD) using FMT. For instance, in a randomized controlled trial, patients with active UC who received FMT achieved clinical remission and mucosal healing at a significantly higher rate than the placebo group. Similarly, a small pilot study of CD patients treated with FMT showed a significant reduction in disease activity scores and an increase in microbial diversity. While the use of FMT for IBD is still in its early stages, these preliminary results suggest that it may be a promising therapeutic option for this challenging disease (Sood et al., 2019; Vermeire & Joossens, 2021).

Fecal microbiota transplantation (FMT) has shown potential in treating Crohn's disease (CD), a type of inflammatory bowel disease (IBD). A meta-analysis of five clinical trials involving 164 CD patients found that FMT led to a significant increase in clinical remission and response rates compared to placebo, but the quality of evidence was deemed low due to small sample sizes and varied administration methods. A study comparing FMT via colonoscopy to placebo in CD patients found a significant increase in remission rates in the FMT group at 12 weeks post-treatment, but the study had limitations, including a small sample size and lack of long-term follow-up (Liu et al., 2020; Paramsothy et al., 2017). While FMT shows promise as a potential treatment for IBD, more high-quality research is needed to fully evaluate its efficacy and safety. The exact mechanisms by which FMT exerts its therapeutic effects in IBD are still not well understood, but it is believed to involve restoration of microbial diversity and modulation of the immune system (Quraishi et al., 2017). Furthermore, FMT has shown potential in the treatment of other gastrointestinal diseases beyond CDI and IBD, including irritable bowel syndrome (IBS), non-alcoholic fatty liver disease (NAFLD), and even neurological disorders such as Parkinson's disease. While the results have been mixed and further research is needed, the potential of FMT to treat a range of gastrointestinal and non-gastrointestinal disorders is a promising area of exploration (Cammarota et al., 2019; Qazi et al., 2021).

FMT in the context of antibiotic-resistant infections

FMT has demonstrated potential in addressing complications arising from antibiotic treatment and the emergence of highly virulent and multidrug-resistant pathogens, such as extended-spectrum β-lactamase-producing bacteria, carbapenem-resistant Enterobacteriaceae, and vancomycin-resistant enterococci (VRE) (Zhang et al., 2021). These bacteria can form reservoirs within the gastrointestinal tract due to routine antibiotic pressure applied in the context of intensive medical care. For instance, patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) are routinely administered antibiotics, which can lead to a significant reduction in microbial diversity and an increase in potential pathogens, including Enterococcus and γ-Proteobacteria (DeFilipp et al., 2019).

The use of FMT can be helpful in such scenarios, as it restores microbial diversity and potentially reduces the risk of infection. Blooms of specific bacteria like Enterococcus and γ-Proteobacteria within the intestinal tract have been correlated with blood-borne infections in HSCT patients undergoing myeloablative conditioning with chemotherapy and radiation, which disrupts the gut barrier (Peled et al., 2017). Therefore, FMT could potentially play a role in reducing the risk of these infections and improving patient outcomes. Fecal microbiota transplantation (FMT) has shown promise in the treatment of Clostridioides difficile infection (CDI) and has been observed to lead to a loss of vancomycin-resistant enterococci (VRE) dominance in solid organ transplant recipients (Kassam et al., 2013). The use of antibiotics can disrupt the symbiotic relationship between the host and gut microbiota, leading to the search for existence outside the host by commensal organisms (Khoruts & Sadowsky, 2016). This can result in the evolution of antibiotic resistance and pathogenic potential among some commensal organisms, which is closely related. Moreover, antibiotic resistance and virulence traits can exist on mobile genetic elements that can be transferred from one bacterium to another, further exacerbating the development of antibiotic-resistant pathogens (Khoruts & Sadowsky, 2016). By restoring normal microbial gut ecology, FMT could potentially aid in the development of innovative therapeutic techniques for the treatment of infectious diseases that do not promote antibiotic resistance and could even decrease it. Thus, FMT could help in addressing the growing challenge of antibiotic resistance in the medical field and could potentially lead to the development of next-generation FMT-based therapies (Khoruts & Sadowsky, 2016).

Potential of FMT for Treatment of Liver Diseases

Hepatitis B virus (HBV) infection is a significant global public health challenge, with a substantial proportion of patients developing chronic liver diseases like cirrhosis, liver failure, and hepatocellular carcinoma (HCC). The ideal outcome for HBV-infected patients is HBsAg loss, while HBeAg seroconversion is the primary treatment goal for HBeAg-positive chronic hepatitis B (CHB) patients. The currently approved therapies, including oral nucleotide analogue(s) and peg-interferon, have limitations, with only a small percentage of patients achieving HBeAg clearance or seroconversion, even after prolonged antiviral therapy. Recent studies have suggested that the gut microbiota may play a vital role in immune clearance of HBV, and some initial trials have demonstrated the potential therapeutic benefit of fecal microbiota transplantation (FMT) for stubborn CHB patients. However, more significant evidence from large-scale perspective studies is required to validate these findings. (Liu et al., 2021)

Several studies have explored the possible mechanisms underlying how gut microbiota composition can affect HBV infection. CHB infection has been associated with HBV-specific immune responses' dysfunction, leading to failure in treating infected hepatocytes. In animal models, antibiotic use and other risk factors have been shown to impair gut barrier function, increase gut permeability, and result in commensal bacterial translocation from the gut to the liver, suppressed T-cell response in the liver, and prolonged HBV infection. Additionally, genetic background is a key factor in determining outcomes for patients with HBV infection. HBV infection can alter the intestinal microbiota, causing an increase in bacterial translocation and endotoxin load, which can activate Toll-like receptor and facilitate immune-mediated liver injury. Non-Alcoholic Fatty Liver Disease (NAFLD) is a prevalent condition that affects 10-24% of the global population, encompassing various conditions such as simple steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and cancer are strongly associated with NAFLD. Fecal Microbiota Transplantation (FMT) has emerged as a potential therapeutic approach for various metabolic diseases, including NAFLD. Research indicates that FMT

can restore gut microbiota imbalances and reverse steatohepatitis in mouse models of high-fat diet-induced NAFLD. In a randomized clinical trial, patients with NAFLD who underwent FMT from healthy donors experienced significant symptom improvements compared to those who received conventional treatment. Ongoing clinical trials are exploring the efficacy of FMT in treating NAFLD and NASH.

Several studies have shown a link between NAFLD and NASH and changes in gut microbiota composition, including elevated levels of Clostridium, Anaerobacter, Streptococcus, Escherichia, and Lactobacillus in NAFLD patients and higher levels of Proteobacteria, Enterobacteriaceae, and Escherichia in NASH patients. These changes can result in the production of hepatotoxic compounds such as 2-butanone and 4-methyl-2-pentanone and ethanol, activating the nuclear factor-κB (NF-κB) signaling pathway and causing liver damage. Additionally, weakened detoxification pathways in NAFLD patients can cause oxidative damage to hepatocytes, inducing inflammation and steatohepatitis.

- **Alcoholic Liver Disease:**

Alcoholic Liver Disease (ALD) encompasses a range of liver diseases that vary in severity from liver steatosis to alcoholic hepatitis, fibrosis, and cirrhosis. Alcohol abuse can cause liver damage in approximately 20-30% of individuals, and some progress to more severe forms of the disease. The most effective way to prevent and treat ALD is through long-term abstinence from alcohol. Steroid therapy is only recommended for a third of patients with alcoholic hepatitis, and liver transplantation is necessary in the late stages of the disease. However, there are uncertainties regarding transplantation's effectiveness in reducing the risk of infections, post-transplant recurrence, and long waitlist times. Research indicates that gut microbiota may play a vital role in ALD progression, with patients showing different levels and structures of gut microbiota. Certain microbiota have been found to influence ALD progression, such as tryptophan metabolism and ursolic acid, which have been found to improve alcohol-induced liver injury and intestinal oxidative stress in animal models. Fecal microbiota transplantation (FMT) has shown promise as a treatment for ALD, particularly for non-responsive patients who have not undergone liver transplantation. Positive outcomes have been observed in clinical trials, demonstrating that FMT is a safe and efficient therapy for ALD.

- **Autoimmune Hepatitis (AIH):**

Autoimmune Hepatitis (AIH) is a chronic liver disease that results in immune-mediated hepatocyte damage, high levels of serum immunoglobulin G (IgG), and the presence of circulating autoantibodies. AIH can affect individuals of any age and ethnicity, and its main cause is believed to be the loss of tolerance against liver antigens caused by genetic and environmental risk factors, such as pathogens and xenobiotics. AIH can lead to liver cirrhosis, hepatocellular carcinoma (HCC), and even fulminant hepatic failure. It can be classified into two types: juvenile and adult AIH. While corticosteroids are effective in most cases, some patients may still develop fibrosis and cirrhosis. Recent studies using murine models suggest that gut microbiota dysfunction may be an important environmental risk factor in the pathogenesis of AIH.

- **Primary sclerosing cholangitis (PSC):**

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by cholestasis, bile duct stenosis, and hepatic fibrosis. Studies have shown that PSC is closely related to inflammatory bowel disease (IBD), indicating that the gut microbiota plays a crucial role in PSC (Rahman et al., 2020).

Patients with PSC and PSC-IBD have significantly different gut microbiota profiles compared to healthy controls, with a decrease in *Prevotella copri* (P. *copri*) expression (Abrahamsson et al., 2017). Previous studies have demonstrated that P. *copri* can enhance bile acid metabolism and signaling, promote immune tolerance, and improve glucose homeostasis (Pedersen et al., 2016). Additionally, genome-wide association studies have identified some loci that are related to both microbiome composition and PSC, such as fucosyltransferase 2 (FUT2) (Jostins et al., 2012). Germ-free multidrug resistance 2 knockout (mdr2−/−) mouse models have been used to demonstrate the protective role of gut microbiota in PSC (Rahman et al., 2020).

Currently, liver transplantation (LT) is the only therapeutic option for PSC, as there is no effective therapy for the treatment of PSC. However, there is still a risk of recurrent PSC after LT. Based on the protective role of gut microbiota in PSC, recent studies have focused on the therapeutic effects of gut microbiota in PSC. While a few studies have assessed the therapeutic effects of oral antibiotics, such as vancomycin, metronidazole, and minocycline, on PSC, there have been only a limited number of studies on the effects of fecal microbiota transplantation (FMT) on PSC. One pilot study of 10 patients with PSC-IBD found that FMT led to more than a 50% decrease in alkaline phosphatase (ALP) levels in 30% of the patients, with no relevant adverse events (Allegretti et al., 2019). Another case report showed that FMT could significantly improve liver biochemistry, bile acid, and bacterial community in a patient with recurrent bacterial cholangitis in PSC (Liu et al., 2021). However, further studies are required to confirm these findings. Therefore, gut microbiota has emerged as a key environmental risk factor for PSC as an inflammatory disease, and there is a need for more research to explore the potential of FMT as a treatment option for PSC.

- **Hepatocellular Carcinoma (HCC):**

Hepatocellular Carcinoma (HCC) is a highly aggressive tumor that is often diagnosed at an advanced stage, leading to poor median survival rates ranging from 6-20 months. By 2025, HCC is expected to affect over one million cases worldwide (El-Serag, 2011). While liver transplant (LT) is considered a standard treatment for early-stage HCC in many countries, patients with advanced HCC, whose tumor size and number exceed Milan criteria, have a low 5-year survival rate following LT (Marrero et al., 2018). HCC is typically associated with liver cirrhosis, characterized by inflammation and hepatocellular proliferation, which may lead to HCC recurrence. Recent animal studies have shown that the gut microbiota and its metabolites can influence intrahepatic and peripheral inflammatory and immune responses in HCC. Gut microbiota can promote the development of HCC via the gut-liver axis, making gut microbiota modulation a potential strategy for HCC prevention (Ren et al., 2018). Although clinical trials involving probiotics have been conducted for HCC, no studies have evaluated the effectiveness of Fecal Microbiota Transplantation (FMT) for HCC. The benefits of FMT for HCC treatment were first demonstrated in a human clinical trial, which showed favourable changes in gene expression profiles and immune cell infiltrates in the tumor microenvironment (Wang et al., 2019). Further studies are needed to evaluate the efficacy of FMT for HCC treatment.

FMT donor selection, screening, and regulation

- **Donor selection:**

Donor screening is an essential step in FMT to prevent adverse events and ensure the safety and efficacy of the procedure. The donor screening process includes online pre-screening, clinical assessment, and laboratory screening to meet the exclusion and inclusion criteria recommended by both the United States and European consensus conference guidelines. Spouses or close relatives

were historically preferred as donors, but clinical evidence has shown that unrelated volunteer donors may be more beneficial in cases where genetics play a role in the disease. The time between screening and donation should be kept as short as possible, not exceeding 21 days, to reduce the risk of contamination. While stool banks have recently emerged to address the challenges of finding eligible donors, their availability is still limited. The methods used for preparing fecal samples for FMT vary among different studies, but there is currently no widely accepted standard for quality and safety control of microbiota.

- **Fecal preparation:**

The optimal method for preparing fecal material for FMT remains uncertain, but studies have shown that frozen FMT is as effective as fresh FMT in improving clinical outcomes for recurrent or refractory Clostridioides difficile infection (CDI). Fresh fecal material is typically mixed with sterile normal sodium chloride and filtered to remove large particles before infusion into the recipient's GI tract. Stool banks have been established to collect, screen, and store fecal material for FMT, which is labelled, tracked, and stored at -80°C until needed. The thawing process must be carefully managed to avoid repetitive thawing and freezing, and the fecal suspension should be infused within 6 hours of thawing. Larger volumes of fecal infusion have been found to be more effective in treating CDI, with volumes less than 50 g associated with a higher risk of treatment failure. Therefore, infusion volumes must be carefully considered for optimal treatment outcomes.

- **Recipient preparation:**

The education and support of patients is crucial before undergoing FMT, regardless of the source of fecal material or route of administration. It is important to note that patients should avoid taking antibiotics 12-48 hours prior to fecal infusion. Preparation for the FMT procedure is similar to that of any other endoscopic procedure, which involves standard bowel preparation. Before infusion of donor faeces, it is necessary to ensure that the bowel is cleared of any contaminated fecal material to ensure a healthy graft. To achieve this, some studies have suggested the use of loperamide one hour before FMT, which can help keep the transplanted faeces in the intestines for at least 4 hours.

- **Delivery methods:**

FMT can be administered through different routes, including upper GI (such as via esophagogastroduodenoscopy (EGD), nasogastric, nasojejunal, or nasoduodenal tube), lower GI (such as via colonoscopy or retention enema), and oral capsule (Brandt et al., 2012; Kassam et al., 2013). However, each method has its own advantages and disadvantages. For example, while the upper GI route can be used in patients with an inflamed colon, there are risks of discomfort during tube placement, aspiration, and the inability to evaluate the colon mucosa or collect mucosa tissue samples (Brandt et al., 2012). Colonoscopy is more effective in recolonizing the entire colon with beneficial bacteria, but it is a relatively invasive, costly, and risky procedure (Brandt et al., 2012; Kassam et al., 2013). Retention enema is less invasive and more affordable, but the donor fecal material can only be delivered to the distal colon and not to the entire colon (Brandt et al., 2012; Kassam et al., 2013).Oral capsule is less invasive and more acceptable to patients, but it is more expensive and requires a large capsule burden (Brandt et al., 2012; Kassam et al., 2013).

Studies have evaluated the different methods of FMT administration, with conflicting results. Some studies have found no significant differences in cure rates between upper and lower GI routes, while others have concluded that the lower GI route is more effective in treating CDI (Kelly et al., 2014;

Moayyedi et al., 2017). A study by Kao and colleagues found that FMT through oral capsules had similar outcomes to colonoscopy in preventing recurrent CDI (Kao et al., 2017). It is important to note that FMT can be a one-time treatment or require multiple doses, depending on the patient's condition and response to therapy (Brandt et al., 2012).

Before undergoing FMT, patients should receive education and support regardless of the source of fecal material or route of administration. Patients should not take antibiotics for 12-48 hours prior to fecal infusion, and a standard bowel preparation is required before the procedure (Brandt et al., 2012). Before the infusion, it is important to clear the bowel of any contaminated fecal material to ensure a healthy graft. Some studies have suggested the use of loperamide one hour before FMT to keep the transplanted faeces in the intestines for at least 4 hours (Brandt et al., 2012; Kelly et al., 2014).

- **Regulation:**

Fecal microbiota transplantation (FMT) is a promising therapy for gastrointestinal disorders, but its regulation varies across different regions. In the United States, the Food and Drug Administration (FDA) considers FMT as an investigational new drug, and clinicians must obtain FDA approval and report any adverse events associated with the procedure. FMT must also comply with the FDA's current Good Manufacturing Practice regulations for human cells, tissues, and cellular and tissue-based products. In contrast, in Europe, FMT is classified as an advanced therapy medicinal product (ATMP), and clinicians must provide evidence of safety, quality, and efficacy to obtain authorization from the European Medicines Agency (EMA) before using it in patients. Regulations for FMT differ in other countries as well. As the field of FMT evolves, regulations are likely to change to ensure the provision of safe and effective care to patients. In the US, the FDA began regulating FMT as a drug in 2013, and obtaining an Investigational New Drug (IND) application is necessary for clinics or healthcare facilities to provide FMT. In 2016, the FDA issued guidance documents on FMT use in treating recurrent Clostridioides difficile infection (rCDI), establishing donor selection criteria, screening for communicable diseases, informed consent, and reporting of adverse events. However, in some cases, such as for treating life-threatening illnesses with no alternative treatments, an IND application may not be necessary.

Regulations on Fecal Microbiota Transplantation (FMT) vary across different countries. For example, FMT is considered as a tissue transplant and is subject to similar regulations as other types of tissue transplantation in Australia and the United Kingdom. However, in countries like Germany and France, there are no specific laws or guidelines governing the use of FMT.

Aside from the FDA, various organizations have also provided guidelines and recommendations for FMT. The American Gastroenterological Association (AGA) published guidelines for FMT in patients with Clostridioides difficile infection (CDI), which recommend that FMT should only be considered after standard antibiotic therapy has failed. The AGA guidelines also suggest that donors should be screened for infectious diseases, and FMT material should be tested for infectious agents such as hepatitis and HIV. The Infectious Diseases Society of America (IDSA) also provides guidelines for the treatment of CDI, which include FMT as an option for patients with recurrent CDI.

In Europe, the European Medicines Agency (EMA) has provided guidance on FMT for the treatment of CDI. The EMA recommends that FMT should only be considered after standard antibiotic therapy has failed, and that donors should be screened for potential infectious diseases. The EMA also recommends that FMT material should be tested for infectious agents, and the procedure should be performed in a clinical setting.

As the use of FMT expands to new indications and further research is conducted, guidelines and regulations for FMT are continually evolving. It is crucial for healthcare professionals and patients to stay informed of these guidelines and regulations to guarantee the safe and effective use of FMT.

Future directions and challenges in the development of FMT as a therapeutic approach for infectious and inflammatory diseases

In recent years, there has been increasing interest in exploring the potential of FMT as a treatment option for various infectious and inflammatory diseases beyond CDI and IBD. Research is currently being conducted on the use of FMT to treat metabolic syndrome, autoimmune diseases, neurological disorders, and cancer. To further develop FMT as a therapy, researchers are exploring the use of synthetic microbiota that can be tailored to target specific diseases. Additionally, researchers are investigating the use of FMT in combination with other therapies, such as probiotics or antibiotics. However, there are still several challenges that must be addressed in the development of FMT as a therapeutic approach. These challenges include standardizing donor screening and fecal material preparation, ensuring the safety of the procedure, and understanding the long-term effects on the recipient's microbiome. Furthermore, the mechanisms underlying FMT and its effects on the recipient's immune system and microbiome are still not well understood, which poses a challenge to its widespread adoption. Nonetheless, the potential benefits of FMT as a therapy are significant, and further research into its development and efficacy holds promise for the treatment of a diverse array of diseases.

Fecal microbiota transplantation (FMT) has emerged as a promising treatment approach for various diseases, particularly for recurrent Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD). However, the development of FMT as a therapeutic approach is still facing significant challenges, including the regulatory framework surrounding its use. Currently, FMT is regulated by the US Food and Drug Administration (FDA) as an investigational new drug (IND), which requires strict adherence to certain protocols and guidelines. The regulatory landscape for FMT in other indications beyond CDI and IBD remains uncertain, which may limit patient access to this treatment. As such, there is a growing consensus among researchers and clinicians that the regulatory framework for FMT needs to be updated to reflect the unique nature of this treatment. This includes the development of standardized protocols for donor screening, fecal material preparation, and patient monitoring, as well as clear guidelines for the use of FMT in different disease contexts.

Moreover, the potential use of FMT in outpatient settings raises questions about the appropriate oversight and regulation of the procedure. To ensure that patients are receiving safe and effective treatment while also allowing for innovation and progress in the field, it will be important for regulators to work closely with researchers and clinicians. This will help to ensure that the regulatory framework is up-to-date and responsive to the evolving nature of FMT as a treatment approach.

In addition to regulatory challenges, the lack of trained healthcare professionals and infrastructure for FMT administration poses a significant obstacle to the development of FMT as a therapeutic approach. The specialized skills required for donor screening, fecal material preparation, and FMT administration may not be readily available, particularly in low-resource settings. Furthermore, the infrastructure required for FMT administration, such as endoscopy suites and specialized equipment, may not be widely available in all regions. Addressing these challenges will be essential to ensure that FMT is accessible to patients who may benefit from this treatment approach. The development of FMT as a therapeutic approach faces significant challenges related to regulatory oversight, patient access, and infrastructure and training needs. To overcome these obstacles and realize the potential

benefits of FMT, it will be essential for stakeholders in the field, including regulators, researchers, clinicians, and healthcare providers, to work collaboratively to develop and implement strategies that ensure safe and effective use of FMT for a range of indications beyond CDI and IBD. To fully realize the potential benefits of FMT as a treatment for infectious and inflammatory diseases, several challenges must be overcome. These challenges include the standardization of donor screening and fecal material preparation to ensure its safety and efficacy. In addition, regulatory approval and insurance coverage for FMT in other indications remain uncertain, and there is a need for trained healthcare professionals and infrastructure to administer FMT in low-resource settings. Addressing these challenges will be essential for advancing FMT as a therapeutic approach and improving patient outcomes.

RESULT AND DISCUSSION

The potential of microbiota transplantation, also known as fecal microbiota transplantation (FMT), as a novel approach for treating infectious and inflammatory diseases has garnered significant attention in recent years. FMT involves the transfer of fecal material from a healthy donor into the gastrointestinal tract of a recipient, with the aim of restoring a healthy gut microbiome. This section presents the key findings and discusses the implications of FMT in the treatment of various diseases.

One of the primary areas where FMT has shown remarkable success is in the treatment of Clostridium difficile infection (CDI). Numerous studies have reported high cure rates with FMT, surpassing those achieved with conventional antibiotic therapy alone. The transplantation of healthy fecal material helps to restore the gut microbiota balance, eliminating the overgrowth of C. difficile and resolving the infection. The effectiveness of FMT in CDI has led to its regulatory approval and recognition as a standard treatment option.

In addition to CDI, FMT has shown promise in the management of inflammatory bowel disease (IBD). Studies have demonstrated that FMT can induce remission and reduce disease activity in patients with ulcerative colitis and Crohn's disease. The transfer of healthy microbiota through FMT helps modulate the immune response and restore the microbial diversity in the gut, leading to improved clinical outcomes.

Furthermore, emerging research suggests that FMT may have potential applications beyond CDI and IBD. Preclinical and clinical studies have explored the use of FMT in treating metabolic syndrome, autoimmune diseases, neurological disorders, and liver disorders. While the results are promising, further investigation is needed to establish the safety, efficacy, and optimal protocols for FMT in these conditions.

Despite the promising potential of FMT, several challenges need to be addressed for its widespread adoption. Standardization of donor screening and fecal material preparation protocols is crucial to ensure the safety and quality of transplanted microbiota. Regulatory frameworks must also be developed or updated to provide clear guidelines for the use of FMT in different disease contexts. Additionally, the training of healthcare professionals and the availability of appropriate infrastructure for FMT administration are essential for its successful implementation.

The long-term effects and mechanisms underlying FMT and its impact on the recipient's immune system and microbiome are still not fully understood. Further research is needed to elucidate these aspects and optimize the therapeutic potential of FMT.

CONCLUSION

Microbiota transplantation, specifically fecal microbiota transplantation (FMT), holds significant promise as a novel approach for treating infectious and inflammatory diseases. This review has examined the current state of research in this field, highlighting the potential of FMT in addressing various conditions, including Clostridium difficile infection, inflammatory bowel disease, autoimmune diseases, neurological disorders, and liver disorders.

The findings suggest that FMT has demonstrated favorable outcomes in treating certain infectious diseases, particularly recurrent Clostridium difficile infection, with high cure rates reported in several studies. Moreover, FMT has shown promising results in reducing inflammation and improving symptoms in patients with inflammatory bowel disease. There is also emerging evidence supporting its potential efficacy in other disease contexts, such as metabolic syndrome, autoimmune diseases, and neurological disorders. However, further research is still needed to better understand the mechanisms underlying FMT's therapeutic effects and to determine its long-term safety and efficacy in these conditions.

Standardization of donor screening and fecal material preparation protocols is essential to ensure the safety and effectiveness of FMT. Additionally, regulatory approval and appropriate oversight are necessary to address the unique challenges associated with FMT and to establish guidelines for its use in different disease contexts. The development of trained healthcare professionals and the availability of suitable infrastructure for FMT administration are crucial for its successful implementation.

While FMT holds great potential, it is important to acknowledge the limitations and uncertainties that currently exist in the field. The diversity of microbial populations, individual responses, and long-term effects on the recipient's microbiome and immune system remain areas of ongoing research.

In conclusion, microbiota transplantation, particularly FMT, represents a promising novel approach for the treatment of infectious and inflammatory diseases. With further advancements in research, standardization, regulation, and clinical practice, FMT has the potential to revolutionize the management of these conditions, offering improved outcomes and quality of life for patients. Continued investigation and collaboration among researchers, clinicians, and regulatory bodies are essential to fully unlock the therapeutic potential of microbiota transplantation in the years to come.

REFERENCE

[1] Xu, M., Xu, X., Li, J., Li, F. (**2020**). Association of gut microbiota with host metabolism and inflammatory bowel disease. Frontiers in Microbiology, 11, 156.

[2] Honda, K., Littman, D. R. (**2016**). The microbiota in adaptive immune homeostasis and disease. Nature, 535(7610), 75–84.

[3] Rook, G. A., Raison, C. L., Lowry, C. A. (**2013**). Microbial ‘old friends,’ immunoregulation and socioeconomic status. *Clinical & Experimental Immunology*, 177(1), 1–12.

[4] Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (**2019**). International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 68(12), 2111-2121.

[5] Kang, D. W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., & Khoruts, A. (**2017**). Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome, 5(1), 10.

[6] Lynch, S. V., & Pedersen, O. (**2016**). The human intestinal microbiome in health and disease. *New England Journal of Medicine*, 375(24), 2369-2379.

[7] Bäumler, A. J., & Sperandio, V. (**2016**). Interactions between the microbiota and pathogenic bacteria in the gut. Nature, 535(7610), 85–93.

[8] Kump, P. K., Krause, R., Allerberger, F., Högenauer, C., & et al. (**2020**). Fecal microbiota transplantation – definition, indications, evidence-based guidelines and quality, safety, and regulatory aspects (Part 2). Wiener klinische Wochenschrift, 132(7-8), 190–211.

[9] Petrof, E. O., & Khoruts, A. (**2014**). From stool transplants to next-generation microbiota therapeutics. Gastroenterology, 146(6), 1573–1582.

[10] Lynch, S. V., & Pedersen, O. (**2016**). The human intestinal microbiome in health and disease. *New England Journal of Medicine,* 375(24), 2369–2379.

[11] Van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., et al. (**2013**). Duodenal infusion of donor faeces for recurrent Clostridium.

[12] Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., & Adar, T. (**2018**). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell, 174(6), 1406-1423.

[13] Budden, K. F., Gellatly, S. L., Wood, D. L. A., Cooper, M. A., Morrison, M., Hugenholtz, P., & Hansbro, P. M. (**2017**). Emerging pathogenic links between microbiota and the gut–lung axis. Nature Reviews Microbiology, 15(1), 55-63.

[14] Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Sanders, M. E. (**2014**). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 11(8), 506-514.

[15] Molina-Tijeras, J. A., Gálvez, J., Rodríguez-Cabezas, M. E., & Ruiz-Cabello, F. (**2019**). Probiotics as a Potential Strategy to Modulate Innate Immune Responses in the Treatment of Skin Diseases. Frontiers in Microbiology, 10, 1579.

[16] Zhao, J., Ding, X., & Zheng, J. (**2023**). Fecal microbiota transplantation: An emerging therapy. Infection and Drug Resistance, 16(1), 393-401.

[17] Schnabl, B., & Brenner, D. A. (**2014**). Interactions between the intestinal microbiome and liver diseases. Gastroenterology, 146(6), 1513-1524.

[18] Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (**2013**). Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. *The American journal of gastroenterology*, 108(4), 500-508.

[19] Sartor, R. B. (**2008**). Microbial influences in inflammatory bowel diseases. Gastroenterology, 134(2), 577-594.

[20] Wang, Y., Li, H., Wang, X., Ye, J., Yu, X., Chen, Y., & Chen, D. (**2021**). Soluble factors in fecal microbiota transplantation for rCDI: A single-arm trial. *Journal of Crohn's and Colitis*, jjab127.

[21] Draper, L. A., Ryan, F. J., Smith, M. K., Jalanka, J., Mattila, E., Arkkila, P., & Ross, R. P. (**2018**). Long-term colonisation with donor bacteriophages following successful faecal microbial transplantation. Microbiome, 6(1), 220.

[22] Duerkop, B. A., Clements, C. V., Rollins, D., Rodrigues, J. L. M., & Hooper, L. V. (**2016**). A composite bacteriophage alters colonization by an intestinal commensal bacterium. Proceedings of the National Academy of Sciences, 113(37), 10485-10490.

[23] Wang, J., Lang, T., Shen, J., Dai, J., Tian, L., Wang, X., & Chen, W. (**2019**). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 569(7758), 539-545.

[24] Zuo, T., Wong, S. H., Cheung, C. P., Lam, K. L., Lui, R. N., Cheung, K., & Chan, F. K. (**2018**). Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nature Communications, 9(1), 3663.

[25] Xu, P., et al. (**2020**). Fungal microbiota and digestive diseases: An overview. Medical Mycology, 58(4), 397-410.

[26] Allegretti, J. R., et al. (**2020**). The Fecal Microbiota Transplantation Landscape. Clinical Gastroenterology and Hepatology, 18(9), 2008-2019.

[27] Hui, W., & Li, T. (**2019**). Impact of intestinal fungi and their interaction with bacteria on health and diseases. *Journal of Applied Microbiology*, 127(6), 1460-1471.

[28] Nicholson, J. K., Holmes, E., & Wilson, I. D. (**2004**). Gut microorganisms, mammalian metabolism and personalized health care. Nature Reviews Microbiology, 3(5), 431-438.

[29] Smolinska, A., Blanchet, L., & Buydens, L. M. (**2012**). Widespread metabolomics application of NMR in biofluids and tissues, including humans. Progress in Nuclear Magnetic Resonance Spectroscopy, 60, 43-72.

[30] Vrieze, A., Van Nood, E., & Holleman, F. (**2012**). Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 143(4), 913-916.

[31] Buffie, C.G., Bucci, V., Stein, R.R., McKenney, P.T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A. and Littmann, E., **2015**. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature, 517(7533), pp.205-208.

[32] Seekatz, A.M., Aas, J., Gessert, C.E., Rubin, T.A., Saman, D.M., Bakken, J.S. and Young, V.B., **2014**. Recovery of the gut microbiome following fecal microbiota transplantation. MBio, 5(3), pp.e00893-14.

[33] Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J.R., Pfeffer, K. and Coffer, P.J., **2013**. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature, 504(7480), pp.451-455.

[34] Agus, A., Planchais, J., Sokol, H., **2018**. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host & Microbe, 23(6), pp. 716-724.

[35] Buffie, C. G., Bajic, S., & Schloss, P. D. (**2018**). The intestinal microbiota and chronic disorders of the gut. Nature Reviews Gastroenterology & Hepatology, 15(6), 326-342.

[36] Belkaid, Y., & Hand, T. W. (**2014**). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121-141.

[37] Round, J. L., & Mazmanian, S. K. (**2009**). The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews Immunology, 9(5), 313-323.

[38] Wilson, B. C., Vatanen, T., Cutfield, W. S., O'Sullivan, J. M., & Spector, T. D. (**2021**). The superorganism of the human microbiome and its potential to influence health. Annual Review of Public Health, 42, 69-87.

[39] Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., & Scaldaferri, F. (**2017**). International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 66(4), 569–580.

[40] Kelly, C. R., Khoruts, A., Staley, C., Sadowsky, M. J., Abd, M., Alani, M., Bakow, B., Curran, P., McKenney, J., Tisch, A., Reinert, S. E., Machan, J. T., Brandt, L. J., & Fischer, M. (**2015**). Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: A randomized trial. *Annals of Internal Medicine*, 163(3), 155–163.

[41] Leffler, D. A., & Lamont, J. T. (**2015**). Clostridium difficile infection. *The New England Journal of Medicine,* 372(16), 1539–1548.

[42] Quraishi, M. N., Widlak, M., Bhala, N., & Moore, D. (**2017**). Price of poo: A cost-effectiveness analysis of faecal microbiota transplantation for recurrent Clostridium difficile infection. Alimentary Pharmacology & Therapeutics, 46(8), 837–846.

[43] van Nood, E., Vrieze, A., Nieuwdorp, M., et al. (**2013**). Duodenal infusion of donor faeces for recurrent Clostridium difficile. *The New England Journal of Medicine*, 368(5), 407-415.

[44] Cammarota, G., Ianiro, G., Tilg, H., et al. (**2017**). European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 66(4), 569-580.

[45] Jiang, Z.-D., Ajami, N. J., Petrosino, J. F., Jun, G., Hanis, C. L., & Shah, M. (**2020**). Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridioides difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Alimentary Pharmacology & Therapeutics, 51(12), 1420-1430.

[46] Kelly, C. P., & Kahn, S. (**2015**). Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Annals of Internal Medicine, 163(12), 908-916.

[47] Quraishi, M. N., Widlak, M., Bhala, N., & Moore, D. (**2017**). Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary Pharmacology & Therapeutics, 46(5), 479-493.

[48] Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (**2019**). The evolving landscape of fecal microbiota transplantation in inflammatory bowel disease. Inflammatory Bowel Diseases, 25(2), e18-e30.

[49] Vermeire, S., & Joossens, M. (**2021**). Fecal microbiota transplantation in IBD: indications, methods, and outcomes. Nature Reviews Gastroenterology & Hepatology, 18(2), 84-96.

[50] Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., & Costello, S. P. (**2019**). International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. Gut, 68(12), 2111-2121.

[51] Liu, Y., Zhang, L., Wang, X., Wang, Z., Zhang, J., Jiang, R., & Wei, H. (**2020**). Efficacy and safety of fecal microbiota transplantation for the treatment of inflammatory bowel disease: a systematic review and meta-analysis. Frontiers in medicine, 7, 597590.

[52] Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., & Borody, T. J. (**2017**). Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet, 389(10075), 1218-1228.

[53] Qazi, T., Amaratunga, T., Barnes, E. L., Fischer, M., Kassam, Z., Allegretti, J. R., & Smith, M. (**2021**). Fecal microbiota transplantation: restoring the injured microbiome in gastrointestinal disease. Digestive diseases and sciences, 66(3), 782-798.

[54] Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. **(2017).** Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Alimentary pharmacology & therapeutics, 46(5), 479-493.

[55] DeFilipp, Z., Bloom, P.P., Torres, S., et al. (**2019**). Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. *New England Journal of Medicine*, 381(21), 2043-2050.

[56] Peled, J.U., Gomes, A.L.C., Devlin, S.M., et al. (**2017**). Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. *New England Journal of Medicine*, 377(24), 2403-2414.

[57] Zhang, H., Liao, N., Li, Y., et al. (**2021**). The use of fecal microbiota transplantation in treating antibiotic-associated diarrhea and recurrent Clostridioides difficile infection: A systematic review and meta-analysis. Scientific Reports, 11, 2038.

[58] Khoruts, A., & Sadowsky, M. J. (**2016**). Understanding the mechanisms of faecal microbiota transplantation. Nature Reviews Gastroenterology & Hepatology, 13(9), 508–516.

[59] Abrahamsson, H., Gustavsson, L., Andersson, R., Färkkilä, M., Hultcrantz, R., Marschall, Broomé, U. (**2017**). Impaired gut microbiota and bile acid metabolism in patients with primary sclerosing cholangitis. *Scandinavian Journal of Gastroenterology*, 52(11), 1262–1268.

[60] Allegretti, J. R., Kassam, Z., Carrellas, M., Mullish, B. H., Marchesi, J. R., Pechlivanis, A. Gerardin, Y. (**2019**). Fecal microbiota transplantation in patients with primary sclerosing cholangitis: A pilot clinical trial. *American Journal of Gastroenterology*, 114(7), 1071–1079.

[61] El-Serag, H. B. **(2011).** Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 136(4), 1479-1491.

[62] Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., & Heimbach, J. K. (**2018**). Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 68(2),

723-750.

[63] Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., & Xu, S. (**2018**). Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 67(5), 1014-1022.

[64] Wang, J., Wang, Y., Zhang, X., Liu, J., Zhang, Q., Zhao, Y., & Liu, Z. (**2019**). Gut microbial dysbiosis is associated with development and progression of hepatocellular carcinoma in mice. *Journal of Gastroenterology and Hepatology*, 34(12), 2208-2216.

[65] Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Surawicz, C. (**2012**). Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. *American Journal of Gastroenterology*, 107(7), 1079–1087.

[66] Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., ACG Clinical Guidelines Committee. (**2014**). Update on fecal microbiota transplantation 2015: Indications, methodologies, mechanisms, and outlook. Gastroenterology, 149(1), 223–237.